Resistance to anti-HCV protease inhibitors

Curr Opin Virol. 2011 Dec;1(6):599-606. doi: 10.1016/j.coviro.2011.10.001. Epub 2011 Oct 28.

Abstract

The era of direct acting antiviral therapy for HCV infection has dawned with the recent approval of the NS3 protease inhibitors telaprevir and boceprevir. The development of DAA therapy is an exciting advance for clinicians and patients, but it will also bring new challenges. For the first time, drug resistance has become an issue to consider in the management of HCV. This brief review summarizes the current literature concerning resistance to the HCV NS3 protease inhibitors, both experimental and clinical, and identifies the key questions facing the field.

Publication types

  • Review

MeSH terms

  • Drug Resistance, Viral
  • Hepacivirus / enzymology
  • Hepacivirus / physiology*
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / virology
  • Humans
  • Models, Molecular
  • Oligopeptides / pharmacology*
  • Oligopeptides / therapeutic use
  • Proline / analogs & derivatives*
  • Proline / pharmacology
  • Proline / therapeutic use
  • Protease Inhibitors / pharmacology*
  • Protease Inhibitors / therapeutic use
  • Viral Nonstructural Proteins / antagonists & inhibitors*
  • Viral Nonstructural Proteins / metabolism
  • Virus Replication / drug effects

Substances

  • NS3 protein, hepatitis C virus
  • Oligopeptides
  • Protease Inhibitors
  • Viral Nonstructural Proteins
  • telaprevir
  • N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
  • Proline